Pluvicto Market By Indication (Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Advanced PSMA-Positive Prostate Cancer), By Line of Therapy (First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy), By Route of Administration (Intravenous (IV), Intramuscular (IM)), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies, Retail Pharmacies), By End-User (Hospitals, Specialty Cancer Clinics, Radiotherapy Centers, Academic and Research Institutes, Diagnostic Imaging Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Pluvicto Market: Market Overview

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing prevalence of prostate cancer worldwide driving demand.

3.2.2. Increased adoption of targeted therapies improving patient survival rates.

3.2.3. Expanding healthcare infrastructure boosting market growth in emerging economies.

3.3. Key industry pitfalls & challenges

3.3.1. High cost of treatment limiting accessibility in low-income regions.

3.3.2. Stringent regulatory approval processes slowing market penetration rates.

3.3.3. Competitive market with alternative therapies offering similar benefits.

3.4. Market Opportunities

3.4.1. Growing focus on personalized medicine opening new market avenues.

3.4.2. Strategic partnerships between pharmaceutical companies enhancing research and development.

3.4.3. Potential for market growth in underdeveloped regions with increasing awareness.

3.5. Disease pathophysiology

3.6. Disease Diagnosis

3.7. Disease treatment and management

3.8. Standard of care guidelines

3.9. Regulatory landscape

3.10. Industry experts view

3.11. Market drivers & opportunities

3.12. Competitive landscape

3.12.1. Company Market Share

3.12.2. Market Positioning

3.12.3. Strategy framework

3.12.4. Recent Acquisitions & Mergers

4. Pluvicto Market, Epidemiology and Forecast Analysis

4.1. Patient Journey Analysis

4.1.1. Disease overview and progression

4.1.2. Pharmacoeconomics

4.1.3. Prevalent cases

4.1.4. Diagnosed prevalent cases

4.1.5. Segment-specific cases

4.2. Market Share Analysis

4.2.1. Drug Launch date

4.2.2. Drug Uptake

4.2.3. Time to peak

4.2.4. Peak share

4.2.5. Scenario analysis

4.2.6. Real-world evidence (RWE) analysis

4.2.7. Standard treatment protocol

4.2.8. Off-label use analysis

4.3. Dosage and Regimen Analysis

4.3.1. Safety and Efficacy

4.3.2. Dose of drug

4.3.3. Frequency of drug

4.3.4. Route of Administration

4.3.5. Duration

4.3.6. Drug Formulation

4.3.7. Other factors impacting dosage regimen

4.4. Revenue Analysis

4.4.1. Annual doses

4.4.2. Price per dose

4.4.3. Compliance

4.4.4. Adherence and Persistency

4.4.5. Discounts and rebates

4.4.6. Early access program

4.4.7. Reimbursement status

5. Pluvicto Market, By Indication

5.1. Overview Dynamics

5.1.1. Market Revenue Share, By Indication, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Metastatic Castration-Resistant Prostate Cancer (mCRPC)

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Advanced PSMA-Positive Prostate Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Pluvicto Market, By Line of Therapy

6.1. Overview Dynamics

6.1.1. Market Revenue Share, By Line of Therapy, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. First-Line Therapy

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Second-Line Therapy

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Third-Line and Later Therapy

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Pluvicto Market, By Route of Administration

7.1. Overview Dynamics

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Intravenous (IV)

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Intramuscular (IM)

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Pluvicto Market, By Distribution channel

8.1. Overview Dynamics

8.1.1. Market Revenue Share, By Distribution channel, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospital Pharmacies

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Specialty Pharmacies

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Online Pharmacies

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Retail Pharmacies

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Pluvicto Market, By End-user

9.1. Overview Dynamics

9.1.1. Market Revenue Share, By End-user, 2025 & 2035

9.1.2. Key Market Trends, Growth Factors, & Opportunities

9.2. Hospitals

9.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.3. Specialty Cancer Clinics

9.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.4. Radiotherapy Centers

9.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.5. Academic and Research Institutes

9.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.6. Diagnostic Imaging Centers

9.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

10. Pluvicto Market, Country Market Forecast and Analysis

10.1. Overview

10.1.1. Global Market Revenue Share, By Region, 2025 & 2035

10.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

10.2. North America

10.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

10.2.2. North America Market Revenue, By Indication, 2025-2035

10.2.3. North America Market Revenue, By Line of Therapy, 2025-2035

10.2.4. North America Market Revenue, By Route of Administration, 2025-2035

10.2.5. North America Market Revenue, By Distribution Channel, 2025-2035

10.2.6. North America Market Revenue, By End-user, 2025-2035

10.2.7. The U.S.

10.2.7.1. U.S. Market Revenue, By Indication, 2025-2035

10.2.7.2. U.S. Market Revenue, By Line of Therapy, 2025-2035

10.2.7.3. U.S. Market Revenue, By Route of Administration, 2025-2035

10.2.7.4. U.S. Market Revenue, By Distribution Channel, 2025-2035

10.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

10.2.8. Canada

10.2.8.1. Canada Market Revenue, By Indication, 2025-2035

10.2.8.2. Canada Market Revenue, By Line of Therapy, 2025-2035

10.2.8.3. Canada Market Revenue, By Route of Administration, 2025-2035

10.2.8.4. Canada Market Revenue, By Distribution Channel, 2025-2035

10.2.8.5. Canada Market Revenue, By End-user, 2025-2035

10.3. Europe

10.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

10.3.2. Europe Market Revenue, By Indication, 2025-2035

10.3.3. Europe Market Revenue, By Line of Therapy, 2025-2035

10.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

10.3.5. Europe Market Revenue, By Distribution Channel, 2025-2035

10.3.6. Europe Market Revenue, By End-user, 2025-2035

10.3.7. Germany

10.3.7.1. Germany Market Revenue, By Indication, 2025-2035

10.3.7.2. Germany Market Revenue, By Line of Therapy, 2025-2035

10.3.7.3. Germany Market Revenue, By Route of Administration, 2025-2035

10.3.7.4. Germany Market Revenue, By Distribution Channel, 2025-2035

10.3.7.5. Germany Market Revenue, By End-user, 2025-2035

10.3.8. France

10.3.8.1. France Market Revenue, By Indication, 2025-2035

10.3.8.2. France Market Revenue, By Line of Therapy, 2025-2035

10.3.8.3. France Market Revenue, By Route of Administration, 2025-2035

10.3.8.4. France Market Revenue, By Distribution Channel, 2025-2035

10.3.8.5. France Market Revenue, By End-user, 2025-2035

10.3.9. U.K.

10.3.9.1. U.K. Market Revenue, By Indication, 2025-2035

10.3.9.2. U.K. Market Revenue, By Line of Therapy, 2025-2035

10.3.9.3. U.K. Market Revenue, By Route of Administration, 2025-2035

10.3.9.4. U.K. Market Revenue, By Distribution Channel, 2025-2035

10.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

10.3.10. Italy

10.3.10.1. Italy Market Revenue, By Indication, 2025-2035

10.3.10.2. Italy Market Revenue, By Line of Therapy, 2025-2035

10.3.10.3. Italy Market Revenue, By Route of Administration, 2025-2035

10.3.10.4. Italy Market Revenue, By Distribution Channel, 2025-2035

10.3.10.5. Italy Market Revenue, By End-user, 2025-2035

10.3.11. Spain

10.3.11.1. Spain Market Revenue, By Indication, 2025-2035

10.3.11.2. Spain Market Revenue, By Line of Therapy, 2025-2035

10.3.11.3. Spain Market Revenue, By Route of Administration, 2025-2035

10.3.11.4. Spain Market Revenue, By Distribution Channel, 2025-2035

10.3.11.5. Spain Market Revenue, By End-user, 2025-2035

10.4. Asia Pacific

10.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

10.4.2. Asia Pacific Market Revenue, By Indication, 2025-2035

10.4.3. Asia Pacific Market Revenue, By Line of Therapy, 2025-2035

10.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

10.4.5. Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

10.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

10.4.7. China

10.4.7.1. China Market Revenue, By Indication, 2025-2035

10.4.7.2. China Market Revenue, By Line of Therapy, 2025-2035

10.4.7.3. China Market Revenue, By Route of Administration, 2025-2035

10.4.7.4. China Market Revenue, By Distribution Channel, 2025-2035

10.4.7.5. China Market Revenue, By End-user, 2025-2035

10.4.8. Japan

10.4.8.1. Japan Market Revenue, By Indication, 2025-2035

10.4.8.2. Japan Market Revenue, By Line of Therapy, 2025-2035

10.4.8.3. Japan Market Revenue, By Route of Administration, 2025-2035

10.4.8.4. Japan Market Revenue, By Distribution Channel, 2025-2035

10.4.8.5. Japan Market Revenue, By End-user, 2025-2035

10.4.9. India

10.4.9.1. India Market Revenue, By Indication, 2025-2035

10.4.9.2. India Market Revenue, By Line of Therapy, 2025-2035

10.4.9.3. India Market Revenue, By Route of Administration, 2025-2035

10.4.9.4. India Market Revenue, By Distribution Channel, 2025-2035

10.4.9.5. India Market Revenue, By End-user, 2025-2035

10.4.10. Australia

10.4.10.1. Australia Market Revenue, By Indication, 2025-2035

10.4.10.2. Australia Market Revenue, By Line of Therapy, 2025-2035

10.4.10.3. Australia Market Revenue, By Route of Administration, 2025-2035

10.4.10.4. Australia Market Revenue, By Distribution Channel, 2025-2035

10.4.10.5. Australia Market Revenue, By End-user, 2025-2035

10.4.11. South Korea

10.4.11.1. South Korea Market Revenue, By Indication, 2025-2035

10.4.11.2. South Korea Market Revenue, By Line of Therapy, 2025-2035

10.4.11.3. South Korea Market Revenue, By Route of Administration, 2025-2035

10.4.11.4. South Korea Market Revenue, By Distribution Channel, 2025-2035

10.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

10.5. Latin America

10.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

10.5.2. Latin America Market Revenue, By Indication, 2025-2035

10.5.3. Latin America Market Revenue, By Line of Therapy, 2025-2035

10.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

10.5.5. Latin America Market Revenue, By Distribution Channel, 2025-2035

10.5.6. Latin America Market Revenue, By End-user, 2025-2035

10.5.7. Brazil

10.5.7.1. Brazil Market Revenue, By Indication, 2025-2035

10.5.7.2. Brazil Market Revenue, By Line of Therapy, 2025-2035

10.5.7.3. Brazil Market Revenue, By Route of Administration, 2025-2035

10.5.7.4. Brazil Market Revenue, By Distribution Channel, 2025-2035

10.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

10.5.8. Argentina

10.5.8.1. Argentina Market Revenue, By Indication, 2025-2035

10.5.8.2. Argentina Market Revenue, By Line of Therapy, 2025-2035

10.5.8.3. Argentina Market Revenue, By Route of Administration, 2025-2035

10.5.8.4. Argentina Market Revenue, By Distribution Channel, 2025-2035

10.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

10.5.9. Mexico

10.5.9.1. Mexico Market Revenue, By Indication, 2025-2035

10.5.9.2. Mexico Market Revenue, By Line of Therapy, 2025-2035

10.5.9.3. Mexico Market Revenue, By Route of Administration, 2025-2035

10.5.9.4. Mexico Market Revenue, By Distribution Channel, 2025-2035

10.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

10.6. MEA

10.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

10.6.2. MEA Market Revenue, By Indication, 2025-2035

10.6.3. MEA Market Revenue, By Line of Therapy, 2025-2035

10.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

10.6.5. MEA Market Revenue, By Distribution Channel, 2025-2035

10.6.6. MEA Market Revenue, By End-user, 2025-2035

10.6.7. Saudi Arabia

10.6.7.1. Saudi Arabia Market Revenue, By Indication, 2025-2035

10.6.7.2. Saudi Arabia Market Revenue, By Line of Therapy, 2025-2035

10.6.7.3. Saudi Arabia Market Revenue, By Route of Administration, 2025-2035

10.6.7.4. Saudi Arabia Market Revenue, By Distribution Channel, 2025-2035

10.6.7.5. Saudi Arabia Market Revenue, By End-user, 2025-2035

10.6.8. United Arab Emirates

10.6.8.1. United Arab Emirates Market Revenue, By Indication, 2025-2035

10.6.8.2. United Arab Emirates Market Revenue, By Line of Therapy, 2025-2035

10.6.8.3. United Arab Emirates Market Revenue, By Route of Administration, 2025-2035

10.6.8.4. United Arab Emirates Market Revenue, By Distribution Channel, 2025-2035

10.6.8.5. United Arab Emirates Market Revenue, By End-user, 2025-2035

10.6.9. South Africa

10.6.9.1. South Africa Market Revenue, By Indication, 2025-2035

10.6.9.2. South Africa Market Revenue, By Line of Therapy, 2025-2035

10.6.9.3. South Africa Market Revenue, By Route of Administration, 2025-2035

10.6.9.4. South Africa Market Revenue, By Distribution Channel, 2025-2035

10.6.9.5. South Africa Market Revenue, By End-user, 2025-2035

11. Company Profile

11.1. Novartis

11.1.1. Business Overview

11.1.2. Financial Performance

11.1.3. Product/Service Offerings

11.1.4. Strategies & recent developments

11.1.5. SWOT Analysis

11.2. Bayer

11.2.1. Business Overview

11.2.2. Financial Performance

11.2.3. Product/Service Offerings

11.2.4. Strategies & recent developments

11.2.5. SWOT Analysis

11.3. Lantheus Medical Imaging

11.3.1. Business Overview

11.3.2. Financial Performance

11.3.3. Product/Service Offerings

11.3.4. Strategies & recent developments

11.3.5. SWOT Analysis

11.4. Cardinal Health

11.4.1. Business Overview

11.4.2. Financial Performance

11.4.3. Product/Service Offerings

11.4.4. Strategies & recent developments

11.4.5. SWOT Analysis

11.5. GE Healthcare

11.5.1. Business Overview

11.5.2. Financial Performance

11.5.3. Product/Service Offerings

11.5.4. Strategies & recent developments

11.5.5. SWOT Analysis

11.6. Siemens Healthineers

11.6.1. Business Overview

11.6.2. Financial Performance

11.6.3. Product/Service Offerings

11.6.4. Strategies & recent developments

11.6.5. SWOT Analysis

11.7. Astellas Pharma

11.7.1. Business Overview

11.7.2. Financial Performance

11.7.3. Product/Service Offerings

11.7.4. Strategies & recent developments

11.7.5. SWOT Analysis

11.8. Eli Lilly and Company

11.8.1. Business Overview

11.8.2. Financial Performance

11.8.3. Product/Service Offerings

11.8.4. Strategies & recent developments

11.8.5. SWOT Analysis

11.9. Ipsen

11.9.1. Business Overview

11.9.2. Financial Performance

11.9.3. Product/Service Offerings

11.9.4. Strategies & recent developments

11.9.5. SWOT Analysis

11.10. Merck Group

11.10.1. Business Overview

11.10.2. Financial Performance

11.10.3. Product/Service Offerings

11.10.4. Strategies & recent developments

11.10.5. SWOT Analysis